ClinicalTrials.gg
Sign In
RecruitingNCT03676868BioMAVUpdated Jun 25, 2025

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

An observational study in Cerebral Arteriovenous Malformations and Ruptured or Unruptured Cerebral Arteriovenous Malformations, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 1 site in France. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

From the registry’s dates

  • Started Nov 2018; still recruiting 7 years 11 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
300
Ages
0 Years and older
Sex
All
01

Study summary

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation.

The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke.

The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

02

Conditions studied

  • Cerebral Arteriovenous Malformations
  • Ruptured or Unruptured Cerebral Arteriovenous Malformations
03

In context

Intracranial Arteriovenous Malformations

43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.

This study's planned enrollment of 300 is above the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.

Browse Intracranial Arteriovenous Malformations studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Browse Fondation Ophtalmologique Adolphe de Rothschild studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patient with a cerebral arterioveinus malformation for which an intervention (endovascular treatment or surgery) or only clinical monitoring is planned

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years old
  • Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring
  • Express consent to participate in the study

And

  • children
  • Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority

Exclusion criteria

Exclusion Criteria:

  • Patient benefiting from a legal protection measure
  • Pregnant or breast feeding woman
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic

    associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome

    Time frame: 6 months

  2. Associaton between dosage of platelet and the arteriovenous malformation pronostic

    Dosage of platelet in blood samples and correlation with clinical outcome

    Time frame: 6 months

  3. Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic

    Dosage of neutrophilic in blood samples and correlation with clinical outcome

    Time frame: 6 months

  4. Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic

    Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Fondation Ophtalmologique Rotschild
    Paris, 75019, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2018 (actual). Primary completion is estimated for Nov 2028, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 19, 2018
StartActual
Nov 20, 2018
Primary completionEst.
Nov 19, 2028
CompletionEst.
Nov 19, 2028
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03676868
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
Nov 20, 2018
Primary completion
Nov 19, 2028 (estimated)
Completion
Nov 19, 2028 (estimated)
Last update
Jun 25, 2025

Study contacts

Amélie Yavchitz
Contact
ayavchitz@for.paris
01 48 63 64 54 ext. +33
Jean Philippe DESILLES
Contact
jp.desilles@for.paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Intracranial Arteriovenous Malformations →

Other studies from this sponsor

Fondation Ophtalmologique Adolphe de Rothschild →

Start the discussion